Market cap
$7 Mln
Recently Viewed
Clear AllMarket cap
$7 Mln
Revenue (TTM)
$5 Mln
P/E Ratio
--
P/B Ratio
0.4
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-30 Mln
ROE
-1.6 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
0.3
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
2,873,960
CFO
$-187.72 Mln
EBITDA
$-189.92 Mln
Net Profit
$-202.39 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Brickell Biotech (BBI)
| -83.2 | -11.3 | -57.5 | -90.4 | -74.3 | -68.7 | -57.8 |
|
BSE Sensex*
| -8.7 | 5.4 | -7.7 | -4.0 | 8.1 | 9.7 | 11.8 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Brickell Biotech (BBI)
| -41.4 | -85.5 | -70.5 | -48.0 | -81.8 | -35.4 | -20.4 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Brickell Biotech (BBI)
|
1.7 | 6.8 | 4.6 | -29.9 | -643.2 | -147.4 | -- | 0.4 |
| 74.8 | 10,475.8 | 1,091.0 | 202.3 | 31.6 | 31.3 | 46.8 | 18.4 | |
| 43.7 | 11,095.1 | 2,320.1 | 782.6 | 39.0 | 35.5 | 15.7 | 5.1 | |
| 87.6 | 11,613.4 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 64.0 | 7,577.6 | 1,396.6 | 316.9 | 59.8 | 153.6 | 25 | 154.4 | |
| 266.0 | 7,831.1 | 389.1 | 204.8 | 41.5 | 18.9 | 38.9 | 6.4 | |
| 513.7 | 11,844.1 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 19.7 | |
| 417.5 | 11,924.8 | 2,678.3 | 460.4 | 21.1 | 103.2 | 26.2 | 19.9 | |
| 99.0 | 7,822.0 | 0.0 | -425.4 | -- | -36.7 | -- | 6.3 | |
| 324.2 | 9,029.2 | 0.0 | -303.3 | -- | -45.8 | -- | 10.3 |
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops... sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado. Read more
Co-Founder & Chairman
Mr. Reginald L. Hardy M.B.A., R.Ph.
Co-Founder & Chairman
Mr. Reginald L. Hardy M.B.A., R.Ph.
Headquarters
Boulder, CO
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Brickell Biotech Inc (BBI) is $1.73 (NASDAQ) as of 09-Nov-2022 09:30 EDT. Brickell Biotech Inc (BBI) has given a return of -74.28% in the last 3 years.
Since, TTM earnings of Brickell Biotech Inc (BBI) is negative, P/E ratio is not available.
The P/B ratio of Brickell Biotech Inc (BBI) is 0.41 times as on 19-Apr-2024, a 90 discount to its peers’ median range of 4.29 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
|
2017
|
--
|
--
|
The 52-week high and low of Brickell Biotech Inc (BBI) are Rs -- and Rs -- as of 04-May-2026.
Brickell Biotech Inc (BBI) has a market capitalisation of $ 7 Mln as on 19-Apr-2024. As per SEBI classification, it is a company.
Before investing in Brickell Biotech Inc (BBI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.